Table 1.
Medicines and Healthcare products Regulatory Agency (MHRA) indications of anti-programmed cell death protein 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) monoclonal antibodies, obtained 25 March 2023
| Protein target | Immune checkpoint inhibitor | Cancer | ||||||
| Breast | Colorectal | Head and neck | Lung | Melanoma | Ovarian | Prostate | ||
| PD-1 | Cemiplimab13 | – | – | – | A | – | – | – |
| Dostarlimab14 | – | – | – | – | – | – | – | |
| Nivolumab15 | – | A | A | A | A | – | – | |
| Pembrolizumab16 | A | A | A | A | A | – | – | |
| PD-L1 | Atezolizumab17 | A | – | – | A | – | – | – |
| Avelumab18 | – | – | – | – | – | – | – | |
| Durvalumab19 | – | – | – | A | – | – | – | |
‘A’ represents immune checkpoint inhibitors with at least one approved indication for the cancer type either as monotherapy or as part of combination therapy.